Anant Vinjamoori, chief medical officer of Hims, which plans to offer the peptides if the FDA does reclassify them
Extensive preclinical research shows TB-500 stimulates angiogenesis, promotes wound healing, reduces inflammation, inhibits apoptosis, and enhances tissue perfusion in models of muscle, tendon, ligament, and dermal injury
Background BPC-157 was initially synthesized in the early 1990s and studied for its cytoprotective properties as an anti-ulcer agent
BPC-157 is an investigational synthetic peptide that has not been approved by the FDA for any use
They can help boost collagen production, improve skin texture and tone, and provide numerous other health benefits
Intrinsic factor production often decreases with aging